AFP
IOVA icon

Ausdal Financial Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Ausdal Financial Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$2K – 617
2015
Q4 		$2K Buy
+200
New +$1.39K ﹤0.01% 1220

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Ausdal Financial Partners's IOVA Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Iovance Biotherapeutics (IOVA) in Q1 2016, closing a stake of 200 shares — an estimated $2K sold.

Ausdal Financial Partners first reported a position in IOVA in Q4 2015 and held it in 1 quarter. The position peaked at $2K in Q4 2015. 77 funds tracked by Wall St. Rank hold IOVA as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Iovance Biotherapeutics position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 200 Iovance Biotherapeutics shares in Q1 2016, an estimated $2K.
  • Ausdal Financial Partners first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Iovance Biotherapeutics position peaked at $2K in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.